Elsevier launches new PharmaPendium, empowering pharma companies to bring novel drugs to market faster and increase success of regulatory submissions

Elsevier, a global leader in information and data analytics, has launched the new PharmaPendium, sharpening the translational view of a platform that combines extensive preclinical and clinical data, including complete Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval packages, with predictive tools to accelerate drug development. PharmaPendium enables companies to make faster, more informed decisions about what drug candidates to advance. Pharma professionals and researchers can use the tool to benchmark against competitors, prioritize safety and efficacy, and develop effective strategies for regulatory submissions. The depth and reliability of the platform’s data means PharmaPendium is already trusted by the FDA, Pharmaceuticals and Medical Devices Agency (PMDA) and the top 20 global pharma companies.

“Translation of preclinical research findings to humans in an efficient but safe way is one of the greatest challenges facing drug developers. We designed the new PharmaPendium to solve this. The platform leverages Elsevier’s expertise in curating scientific data and presents it in an intuitive and meaningful way for pharma professionals,” adds Olivier Barberan, Director of Translational Medicine Solutions at Elsevier. “This improved access to highly relevant data plus predictive tools enhances regulatory success, safeguarding the massive investments of pharma companies.”

PharmaPendium’s advanced predictive tools include the Drug-Drug Interaction Risk Calculator (DDIRC) and Safety Margin Tool. These solutions empower researchers to accurately predict harmful drug-drug interactions and off-target related clinical adverse events, and to optimize nonclinical studies and reduce animal testing. They were co-designed to meet industry needs and align with regulatory guidance. Elsevier collaborated with Novartis on the Safety Margin Tool, and with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others on the DDIRC.

Today, 93% of drugs entering clinical trials fail to secure regulatory approval. Better understanding of first-in-human dose selection, optimal study endpoints and mitigating adverse events improves regulatory success. Yet translation from preclinical studies to post-market data analysis is time-consuming and expensive. The new PharmaPendium helps overcome these challenges with:

• Enhanced visualization tools to more easily gain insights from vast quantities of data

• Intelligent autocomplete to increase discoverability and identify important concepts

• Improved search results interface to quickly access key data, such as drug metabolism and pharmacokinetics (DMPK), efficacy and chemistry, extracted from leading data sources, including:

  • Complete FDA and EMA approval packages and FDA advisory committee documents

  • 19 million reports from the FDA Adverse Event Reporting System (FAERS)

  • DESI (Drug Efficacy Study Implementation) documents, Meyler's 16th Edition, Mosby's Drug Consult™️ and scientific articles

PharmaPendium’s high-quality datasets are machine readable and available for off-platform use, allowing companies to embed data into their workflows and employ predictive and scenario modelling. Customers can also access support from Elsevier’s team of domain and data science experts for their data projects.

Learn more about PharmaPendium

エルゼビアについて

エルゼビアは情報分析を専門としたグローバル企業として、研究者や医療専門家の方々を支援し、社会にとっての利益最大化に向けて、科学や医療の進展を支えています。これは、信頼できるエビデンスによるコンテンツと高度なAI対応によるデジタル技術に基づく革新的なソリューションにより、知見の集積や重要な意思決定を支援することで実現されています。

エルゼビアは、全世界で9,700人の従業員（うち技術者2,300人以上）を抱え、140年以上にわたって、研究者、図書館員、アカデミックリーダー、資金提供者、政府、研究開発集約型企業、医師、看護師、将来の医療専門家、教育者など研究・医療分野におけるパートナーの重要な活動を支援してきました。エルゼビアが刊行する3,000誌以上の科学ジャーナルと代表的な参考書には、The Lancet 新しいタブ／ウィンドウで開く、Cell Press 新しいタブ／ウィンドウで開くおよびGray’s Anatomyなどをはじめとする、各分野を代表する主要なタイトルが含まれています。 エルゼビア・ファンデーション 新しいタブ／ウィンドウで開くとの活動を通し、私たちがサービスを提供する地域社会と連携して、開発途上国を含む世界中の医学、研究、医療分野における、インクルージョン＆ダイバーシティ（I&D）の改善に努めています。

エルゼビアは、専門家および企業向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Group 新しいタブ／ウィンドウで開くの一事業を担っています。エルゼビアの事業内容、デジタルソリューション、コンテンツなどの詳細については、www.elsevier.comをご覧ください。